Targeting specific immune cells to find a cure for HIV
Targeting CD127-expressing tissue reservoir cells as a strategy for HIV cure
This study is looking at how a specific type of immune cell helps HIV stick around in the body, and it’s testing a special antibody to see if it can help these cells stop surviving, which could lead to new ways to help people living with HIV feel better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11006843 on NIH RePORTER |
What this research studies
This research investigates how certain immune cells, specifically those expressing CD127, contribute to the persistence of HIV in the body. By using a specialized antibody called 4A10, the study aims to disrupt the signaling pathways that allow these cells to survive and potentially lead to HIV remission. The approach involves testing the effects of this antibody on HIV-infected cells in a controlled laboratory setting, which could provide insights into new treatment strategies for individuals living with HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who have been on antiretroviral therapy and are interested in exploring new treatment options.
Not a fit: Patients who are not living with HIV or those who are not on antiretroviral therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that significantly reduce or eliminate the HIV reservoir in patients, potentially achieving a functional cure.
How similar studies have performed: While targeting immune cells for HIV treatment is a novel approach, similar strategies have shown promise in other areas of HIV research, indicating potential for success.
Where this research is happening
San Francisco, United States
- J. David Gladstone Institutes — San Francisco, United States (Active)
Researchers
- Principal investigator: Roan, Nadia R — J. David Gladstone Institutes
- Study coordinator: Roan, Nadia R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.